VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 17.4% in April

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 100,376 shares, a drop of 17.4% from the March 31st total of 121,535 shares. Based on an average daily volume of 88,009 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.3% of the shares of the stock are sold short.

VYNE Therapeutics Stock Up 0.1%

NASDAQ:VYNE opened at $0.64 on Friday. The company has a fifty day simple moving average of $0.61 and a two-hundred day simple moving average of $0.52. The company has a market cap of $21.21 million, a price-to-earnings ratio of -0.82 and a beta of 1.94. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $1.96.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.15) EPS for the quarter. The business had revenue of $0.13 million during the quarter. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%. On average, analysts expect that VYNE Therapeutics will post -1.1 EPS for the current year.

Hedge Funds Weigh In On VYNE Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of VYNE Therapeutics during the fourth quarter worth $46,000. Two Sigma Investments LP acquired a new position in shares of VYNE Therapeutics during the third quarter worth $74,000. Geode Capital Management LLC grew its stake in shares of VYNE Therapeutics by 64.2% during the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock worth $131,000 after purchasing an additional 88,030 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of VYNE Therapeutics during the fourth quarter worth $147,000. Finally, Shay Capital LLC acquired a new position in shares of VYNE Therapeutics during the third quarter worth $165,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on VYNE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 2nd. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, VYNE Therapeutics has an average rating of “Reduce”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.